Lynch & Associates Gilead Sciences, Inc. Transaction History

Lynch & Associates

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 21, 2020	SELL	$62.1 - $78.08 $1.05 Million - $1.32 Million	-16,865 Closed	0 $0
Q2 2020 Jul 20, 2020	BUY	$72.34 - $84.0 $21,340 - $24,780	295 Added 1.78%	16,865 $1.3 Million
Q1 2020 Apr 28, 2020	BUY	$62.63 - $80.22 $83,611 - $107,093	1,335 Added 8.76%	16,570 $1.24 Million
Q4 2019 Jan 10, 2020	BUY	$61.62 - $67.78 $38,512 - $42,362	625 Added 4.28%	15,235 $990,000
Q3 2019 Oct 03, 2019	SELL	$62.51 - $69.0 $75,012 - $82,800	-1,200 Reduced 7.59%	14,610 $926,000
Q2 2019 Jul 19, 2019	SELL	$61.87 - $69.38 $74,244 - $83,256	-1,200 Reduced 7.05%	15,810 $1.07 Million
Q1 2019 Apr 25, 2019	SELL	$62.53 - $70.05 $12,506 - $14,010	-200 Reduced 1.16%	17,010 $1.11 Million
Q4 2018 Jan 10, 2019	SELL	$60.54 - $79.0 $116,539 - $152,075	-1,925 Reduced 10.06%	17,210 $1.08 Million
Q3 2018 Oct 05, 2018	BUY	$71.28 - $78.92 $42,340 - $46,878	594 Added 3.2%	19,135 $1.48 Million
Q2 2018 Jul 09, 2018	BUY	$64.88 - $75.68 $92,843 - $108,298	1,431 Added 8.36%	18,541 $1.31 Million
Q1 2018 Apr 06, 2018	BUY	$72.84 - $88.8 $89,957 - $109,668	1,235 Added 7.78%	17,110 $1.29 Million
Q4 2017 Jan 04, 2018	BUY	$71.15 - $83.52 $103,167 - $121,104	1,450 Added 10.05%	15,875 $1.14 Million
Q3 2017 Oct 18, 2017	BUY	$72.11 - $85.47 $1.04 Million - $1.23 Million	14,425	14,425 $1.17 Million

1,903

1.02B

12M

9.02M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Lynch & Associates, based on Form 13F filings with the SEC.

Stay updated on Lynch & Associates with notifications on news.